Figure 3. Diffusion tensor imaging in the spinal cords of WT and cerebroside sulfotransferase knock-out (CST-KO) mice.
Image credit: Takano, et. al. 2012 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email [email protected]. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Clinical Scientist Development Award
Sponsor: Doris Duke Charitable Foundation
Description: The Doris Duke Clinical Scientist Development Award provides grants to early-career physician scientists to facilitate their transition to independent clinical research careers. The Clinical Scientist Development Award consists of $150,000 annual direct costs plus $15,000 annual indirect costs for three years.
Deadline: Pre-Proposals due by November 28, 2018.



NEW! Basic Science Postdoctoral Fellowships
Sponsor: AFTD
Description: AFTD Postdoctoral Fellowships provide $55,000 (US)/year for two years to support basic, translational, clinical, and epidemiological research on frontotemporal degeneration (FTD) by outstanding scientists during the postdoctoral phase of their careers. Fellowship projects can address disorders across the full spectrum of FTD disorders: behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal degeneration, and FTD-ALS. The AFTD Basic Science Postdoctoral Fellowship will support projects seeking to answer questions about the biology or pathophysiology of FTD, utilizing tissue samples, biospecimens, animal models, cultured cells (including iPSC-derived neurons or other nervous system cell types), or in silico models. Approaches that employ novel technologies or methodologies for data analysis are especially encouraged.
Deadline: Letter of Intent due by November 30, 2018.



NEW! Clinical Research Postdoctoral Fellowships
Sponsor: AFTD
Description: AFTD Postdoctoral Fellowships provide $55,000 (US)/year for two years to support basic, translational, clinical, and epidemiological research on frontotemporal degeneration (FTD) by outstanding scientists during the postdoctoral phase of their careers. Fellowship projects can address disorders across the full spectrum of FTD disorders: behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal degeneration, and FTD-ALS. The AFTD Clinical Research Postdoctoral Fellowship will support projects utilizing human subjects or datasets derived from human subjects and seeking to answer questions relevant to FTD clinical practice. Approaches that employ novel technologies or methodologies for data analysis are especially encouraged.
Deadline: Letter of Intent due by November 30, 2018.



NEW! Development Grants
Description: MDA Development Grants are awarded to senior postdoctoral researchers on the brink of becoming independent investigators and are intended as seed money to help launch the scientific programs of promising new neuromuscular disease researchers. Development grants total $70,000 per year, for one to three years.
Deadline: Letter of Intent due by December 1, 2018.



NEW! MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by December 1, 2018.



NEW! Research Grants
Sponsor: Thierry Latran Foundation
Description: The Thierry Latran Foundation was established in 2008 to a) finance basic, applied and clinical research with potential therapeutic benefit in sporadic Amyotrophic Lateral Sclerosis and b) to support academic and industrial scientific research efforts in Europe to cure this disease. The Foundation has enabled to reach significant milestones in terms of understanding ALS disease mechanisms and developments. After having paved the way for such progress, the Foundation will, for this new Call, focus on on-going most promising therapeutic targets, to validate or invalidate them. A total amount up to € 800 000 will be awarded.
Deadline: Abstracts due by December 6, 2018.



NEW! McKnight Technological Innovations in Neuroscience
Sponsor: McKnight Foundation
Description: Technological Innovations in Neuroscience Awards support scientists who work on novel and creative approaches to understanding brain function. Established in 1999, the Technological Innovations in Neuroscience Awards provide up to $100,000 per year for two years.
Deadline: Letter of Intent due by December 10, 2018.



NEW! Edward Scolnick Prize in Neuroscience
Description: The Scolnick Prize is awarded annually by the McGovern Institute to recognize outstanding advances in the field of neuroscience. The prize, which is endowed through a gift from Merck to the McGovern Institute, consists of a $150,000 award, plus an inscribed gift.
Deadline: Nominations due by December 15, 2018.



NEW! Neuroscience Prize
Sponsor: Gruber Foundation
Description: The Neuroscience Prize honors scientists for major discoveries that have advanced the understanding of the nervous system. The Prize, established in 2004, comprises an engraved gold laureate pin, an unrestricted cash award of $500,000, and a citation describing the achievement for which the recipient is being honored. It is awarded each year to a person or persons chosen by a distinguished advisory board of neuroscience experts from nominations that are received from around the world.
Deadline: Nominations due by December 15, 2018.



NEW! Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes
Sponsor: National Center for Advancing Translational Sciences
Description: This Funding Opportunity Announcement (FOA) invites researchers to submit R03 or R21 applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
Deadline: Application due by January 7, 2019.



NEW! McKnight Scholar Awards in Neuroscience
Sponsor: McKnight Endowment Fund for Neuroscience
Description: The McKnight Endowment Fund for Neuroscience supports innovative research designed to bring science closer to the day when diseases of the brain and behavior can be accurately diagnosed, prevented, and treated. Scholars will receive $75,000 annually in 2019, 2020 and 2021, subject to an annual review of research progress.
Deadline: Application due by January 7, 2019.



NEW! Klingenstein-Simons Fellowship Awards in Neuroscience
Sponsor: The Esther A. and Joseph Klingenstein Fund
Description: The Klingenstein-Simons Fellowship Awards in the Neurosciences supports, in the early stages of their careers, young investigators engaged in basic or clinical research that may lead to a better understanding of neurological and psychiatric disorders. The award of $225,000 is payable over a three-year period. To qualify, researchers must have a tenure-track appointment or the equivalent and be based in the US.
Deadline: Application due by February 15, 2019.



Biomedical Research Project Grants
Sponsor: Motor Neurone Disease Association
Description: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Applications will begin to be accepted on September 7, 2018. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute. Applications for project grants should not exceed £85,000 per annum (and £255,000 in total) without the prior agreement of the MND Association.
Deadline: Application due by November 2, 2018.



Treat FTD
Sponsor: Alzheimer's Drug Discovery Foundation and the Association for Frontotemporal Degeneration
Description: The Treat FTD fund supports clinical development of novel or repurposed drugs for FTD disorders. This includes support for clinical proof-of-concept and pilot proof-of-mechanism studies. Phase 0/1 studies in healthy volunteers assessing pharmacodynamic outcomes will also be accepted for review. Innovative clinical trial designs and exploratory endpoints are encouraged. Specifically, outcome measures that apply to heterogeneous FTD populations (e.g. markers of pathology due to various causes) should be included in the trial design. Multidomain biomarkers that define grouping should also be considered. The average award is $500,000-$2,000,000 for 1-3 years.
Deadline: Letter of Intent due by November 9, 2018.



Warren Alpert Scholars – Fellowship Award (Neuroscience)
Sponsor: Warren Alpert Foundation
Description: This award will support individual scientists of exceptional creativity who have an MD or PhD degree and who have completed three years of post-doctoral fellowship in a medical school in the basic neurosciences. These awards are given as transitional post-doctoral awards for recipients before they later become a full time faculty member at the Assistant Professor level or higher. The Scholars will be awarded $200,000 annually for two years to cover their salary, lab costs, and related expenses.
Deadline: Application due by January 15, 2019.



CLIN 1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion an IND or IDE filing with the FDA and initiate clinical trial start-up with a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $6M USD. CIRM expects projects under this program to advance rapidly into the clinic and to achieve the proposed IND filing within 18 months.
Deadline: Applications due by 2PM PST on the last business day of each month.



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of a clinical trial for a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $10-15M USD.
Deadline: Applications due by 2PM PST on the last business day of each month.



CLIN 3: Partnering Opportunity for Stem Cell Therapy Registration Clinical Trials
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded clinical trial projects that will directly enable product registration with the Food and Drug Administration (FDA). This award is only available to holders of a current CLIN2 award for a trial that has been deemed by FDA to be sufficient for registration.
Deadline: Applications due by 2PM PST on the the last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clinical Neuroscience Research Grants
Sponsor: Dana Foundation
Description: This grant funds "first-in-man" clinical studies of therapies being developed for brain diseases. Funded studies can receive up to $300,000 payable over three years. Potential applicants may submit a preliminary proposal and budget to determine full proposal eligibility. Applications are not solely restricted to clinical research scientists based in the United States.
Deadline: Applications are accepted on a rolling basis.



DISC 2: The Quest Awards (Stem Cells)
Sponsor: California Institute for Regenerative Medicine (CIRM)
Description: This award program promotes the discovery of promising new stem cell-based technologies that could be translated to enable broad use and ultimately, improve patient care. Projects funded through the Quest Awards should propose technology that is uniquely enabled by human stem/progenitor cells or directly reprogrammed cells, or uniquely enabling for the advancement of stem cell-based therapies. Up to $500,000 USD will be awarded to achieve a candidate that is a diagnostic, a medical device or a tool; or up to $900,000 USD per award to achieve a candidate that is a therapeutic.
Deadline: TBD.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications will be accepted on a rolling basis.



NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Applications are accepted on a rolling basis.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail